HOMOLOGY MODELING AND MOLECULAR DOCKING STUDIES OF HUMAN DPP8 AND DPP9

The development of potent, selective and orally bioactive Dipeptidyl Peptidase IV (DPP4) inhibitors is the real challenge for the treatment of type II diabetes mellitus. Several DPP4 inhibitors are in last-stage of clinical trials, however potential side effects are associated with them may results from other prolyldipeptidases of DPP4 include DPP8 and DPP9. Currently, the crystal structure of DPP4 is available, which is used to build homology models of DPP8 and DPP9 to understand the key residues in their active site for the design of selective DPP4 inhibitors. Further, the docking studies have been performed with potent, selective DPP4 inhibitors such as Sitagliptin, Saxagliptin and Vildagliptin with the aim of explaining the differences in activity and selectivity.